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Abstract
Sex hormone-binding globulin (SHBG) is known as a carrier protein. It is classically thought to be mainly synthesized in the
liver and then secreted into the circulating system, where it binds to sex steroids with a high affinity and modulates the bio-
availability of the hormones. Other organs known to produce SHBG include brain, uterus, testis, prostate, breast and ovary,
and the local expressed SHBG may play an important role in tumor development. However, SHBG expression status and its
clinicopathological significance in ovarian cancer cells are not reported yet. In our present study, we examined and found
the variable SHBG expression in four ovarian cancer cell lines (OV-90, OVCAR-3, SKOV-3 and ES-2) by immunocytochemistry
and Western blotting. We then extended our study to 248 ovarian carcinoma samples, which were collected at The
Norwegian Radium Hospital, Oslo University Hospital with complete clinical information, and discovered that SHBG was
variably expressed in these ovarian carcinomas. Higher level of SHBG expression was significantly associated with more
aggressive histological subtype (p= 0.022), higher FIGO stage (p= 0.018) and higher histological grade (grade of
differentiation, p= 0.020), although association between SHBG expression and OS/PFS was not observed. Our results
demonstrate that ovarian cancer cells produce SHBG and higher SHBG expression in ovarian carcinoma is associated with
unfavorable clinicopathological features.
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Introduction
Ovarian carcinoma is the third commonest malignancy with the
most mortality in gynecologic tumors [1,2]. Hormonal stimulation
of ovarian epithelial cells is suggested as a mechanism for
carcinogenesis of the ovary [3,4]. Sex hormone-binding globulin
(SHBG), a 373-amino-acid glycoprotein, known as a carrier
protein before, is classically thought to be mainly synthesized in
the liver and then secreted into the circulating system [5,6,7],
where it binds to sex steroids with a high affinity and modulates
the bio-availability of the hormones, such as estrogen, androgen
and testosterone [4,8,9]. There are reports that plasma SHBG
may play a role in the development of several sex hormone-related
carcinomas, e.g. breast [10], prostate [11] and ovarian [12]
carcinomas. Circulating SHBG might contribute to the ovarian
carcinogenesis through regulation of sex hormone bio-availability
[4,9,13,14].
Besides liver cells, SHBG is also produced in other organs,
including brain [15,16], uterus [17], testis [18,19], prostate
[20,21], breast [20], ovary [22] and placenta [23], etc. Moreover,
the locally expressed SHBG may participate in the membrane-
based steroid signaling pathway and modulate the androgen
receptor (AR) and estrogen receptor (ER) activations in the
prostate and breast cancer cells, thus it may play a functional role
in the steroid responsiveness of prostate and breast cells and the
perturbation of local SHBG expression could contribute to
prostate and breast cancers [20]. The local expression of SHBG
in human ovarian carcinoma cells and its clinicopathological
correlations are currently unknown.
In our present study, we have investigated the expression of
SHBG in four ovarian cancer cell lines by immunocytochemistry
(ICC) and Western blotting, verifying variable SHBG expression
in these cell lines. Then we extended this study to 248 ovarian
carcinoma patients, in order to explore whether SHBG is
expressed in the human ovarian carcinomas and furthermore
analyze the associations between the local SHBG expression and
clinicopathological features, including age, histological subtype,
histological grade (grade of differentiation), International Feder-
ation of Gynecology and Obstetrics stage (FIGO stage), overall
survival (OS) and progression free survival (PFS).
Materials and Methods
Ethics Statement
The Regional Committee for Medical Research Ethics South of
Norway (S-06277a), The Social- and Health Directorate (06/
3280) and The Data Inspectorate (06/5345) approved the study.
All the patients involved provided their written consent to
PLOS ONE | www.plosone.org 1 December 2013 | Volume 8 | Issue 12 | e83238
participate in this study, and all the written consents were filed in
The Norwegian Radium Hospital, Oslo University Hospital.
Cell Lines
Four ovarian cancer cell lines ES-2, SKOV-3, OVCAR-3 and
OV-90 (from American Type Culture Collection, USA) were
maintained in our laboratory. The ES-2 line was derived from a
patient with ovarian clear cell carcinoma (CCC), and other three
cell lines were derived from malignant ascites of ovarian
adenocarcinoma patients. All cells were cultivated in PRMI
1640 medium supplemented with 10% fetal bovine serum (FBS),
100units/ml penicillin and 100 mg/ml streptomycin at 37uC in a
humidified 5% CO2 incubator.
Immunocytochemistry (ICC)
Cytoblocks were prepared for ICC. For each cell line, the cells
in 80% confluent were harvested by mechanical scraping, and cells
in suspension were spun down at 2000 rpm for 5 minutes before
the supernatant was discarded. The cells were rinsed twice with
phosphate-buffered saline (PBS) to further delete the dead cells or
cell organelles. Four drops of plasma and 2 drops of thrombin
were added to the sedimentation after the supernatant was
discarded, and the contents were carefully mixed by rotating tube
for one minute before coagulation was formed. 4% buffered
formaldehyde was added to the coagulation for cell fixation. The
coagulated mass was then wrapped in a linen paper, put in a
labeled cassette, and placed in 4% buffered formaldehyde. The
material was paraffin-embedded to make cytoblock before being
cut into 3 mm paraffin sections for ICC.
Dako EnvisionTM FLEX+ system (Dako, Denmark) and the
Dako Autostainer were used for ICC. Paraffin sections were
deparaffinized and epitopes were unmasked in PT link with low
pH target retrieval solution (Dako), and then blocked with
peroxidase blocking (Dako) for 5 minutes. The slides were
incubated overnight at 4uC with goat anti-human SHBG antibody
(1:1200, 0.17 mg IgG/ml, cat no. AF2656, R&D,). The secondary
antibody (1:100, mouse anti-goat IgG, Santa Cruz Biotechnology)
was incubated at room temperature for 30 minutes, followed with
mouse linker for 15 minutes and HRP for 30 minutes at room
temperature. Slides were then stained with 3, 39-diaminobenzidine
tetrahydrochloride (DAB, Dako) for 10 minutes and counter-
stained with hematoxylin, dehydrated, and mounted in Richard-
Allan Scientific Cyto seal XYL (Thermo Scientific, Waltham, MA,
USA). Known SHBG-positive human liver tissue was used as
positive control in the same procedure as for ovarian cancer cell
lines or carcinoma slides. The corresponding non-immune goat
IgG was used as negative control at the same concentration as the
primary goat anti-human SHBG antibody.
Intensity scoring was used to evaluate the staining level of
SHBG in the slides, considering the rather homogeneous staining.
The results were separated into four groups: score 0 standing for
negative, while score 1, 2 and 3 representing weakly, moderately,
and strongly stained, respectively.
Western Blotting
For each ovarian carcinoma cell line, the cells were digested
by 0.25% trypsin and EDTA (Invitrogen) when cells grew 80%
confluent and cells in suspension were spun down at 1200 rpm
for 5 minutes before supernatant was discarded. After washed
with ice-cold PBS twice, the cells were dissolved with lysis buffer
containing RIPA buffer (Thermo scientific), 1% PMSF, 1%
aprotinin, 1% leupeptin, 1% pepstatin and 0.5% vanadate by
pipetting gently up and down, put on ice before spun down at
14000 rpm for 15 minutes at 4uC to release total protein in the
supernatant. Total protein was measured by the Bio-Rad
protein assay (Hercules, CA, USA). Equal amount of proteins
from each sample in SDS loading buffer was boiled for 5
minutes and subjected to 10% SDS-PAGE electrophoresis and
then electro-transferred to high-quality polyvinylidene difluoride
(PVDF) membrane in a Trans-Blot apparatus (Bio-rad, Hercu-
les, CA). The membrane was blocked with 5% fat-free milk for
1 hour at room temperature and incubated overnight at 4uC
with goat anti-human SHBG antibody (1:500, 0.4 mg/ml, cat.
no. AF2656, R&D). After washing with PBS-tween 0.05%
(PBST), the blot was incubated with rabbit anti-goat IgG HRP
antibody for 45 minutes at room temperature (1:1000, cat. no.
HAF017, R&D). After several washes with PBST, the blot was
visualized using an enhanced chemiluminescence detection kit
(ECL, Amersham) by following the manual guide.
Clinical Samples
Two hundred and forty-eight surgically removed ovarian
carcinoma samples were enrolled in this study. All patients were
operated at The Norwegian Radium Hospital, Oslo University
Hospital from March 1983 to May 2001. The ages of the
patients range from 19 to 89 years, with a median of 58 years.
The patients were followed up until January 1st 2012. All the
patients were clinically staged by FIGO stage method [24]. The
primary tumors were histologically graded as well, moderately
and poorly differentiated according to WHO recommendations
[24]. Disease progression was determined based on the
definitions outlined by the Gynecologic Cancer Intergroup
[25]. Paraffin-embedded ovarian carcinoma tissues were ob-
tained from the file of the Department of Pathology, and 3 mm
sections were cut and used for morphological examination and
immunohistochemistry (IHC) with the same procedure as for
ICC.
Statistical Analyses
SPSS software (version 18.0) was used for data analysis.
Associations between categorical variables were assessed by Chi-
square tests (Pearson and linear-by-linear as appropriate). Survival
analysis was estimated using the Kaplan-Meier method, and
groups were compared with log-rank tests. For all the analyses,
associations were considered to be significant if the p value was
,0.05.
Results
Expression of SHBG in Ovarian Cancer Cell Lines
Cytoplasmic SHBG was detected by ICC in all of the four
ovarian cancer cell lines ES-2, SKOV-3, OVCAR-3 and OV-90
(Fig. 1A a, b, c, d). Comparatively, it was discovered that ES-2 cell
line was weakly positive (intensity score was 1, Fig. 1A a), SKOV-3
cell line was moderately positive (intensity score was 2, Fig. 1A b),
and OVCAR-3 and OV-90 cell lines were strongly positive
(intensity score was 3 for both, Fig. 1A c and Fig. 1A d,
respectively) for SHBG expression.
The SHBG protein expression in these cell lines was confirmed
by Western blotting as well. This assay revealed an immunore-
active band of 47 kDa (Fig. 1B), in line with the suggested
molecular weight as reported by others [16,19,26]. Quantitative
analysis of the blots revealed that the SHBG expressions in the
four ovarian cancer cell lines agreed with the ICC finding: high in
OV-90 and OVCAR-3, moderate in SKOV-3 and low in ES-2.
SHBG Expression in Ovarian Carcinomas
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SHBG Immunodetection in Clinical Ovarian Carcinoma
Samples
Immunoreactive SHBG was variably detected in the ovarian
carcinoma cells in all the ovarian primary tumor samples (Fig. 2).
The immunostaining was limited to cytoplasm and cell membrane
of ovarian carcinoma cells, and the nuclei were never stained. In
addition to the positive tumor cells, endothelial cells were also
immunoreactive for SHBG.
The immunostaining level of SHBG was scored by the intensity
scoring with the same criteria as for ICC, for it was also relatively
homogenous in each sample. According to the IHC score, the 248
samples were divided into 3 groups: weak expression group
(n = 65), moderate expression group (n = 93), and strong expres-
sion group (n= 90). In addition, carcinoma cells at the invasive
front/infiltration front [27,28] were more strongly stained than
other tumor cells in the same primary tumor (Fig. 2d).
Clinicopathological Associations
The associations of clinical features including age, histology,
FIGO stage and grade of differentiation with SHBG expression in
the ovarian carcinomas were shown in Table 1. SHBG expression
was positively associated with histological subtype (p=0.022),
FIGO stage (p=0.018) and histological grade (grade of differen-
tiation, p=0.020). For tumor histological subtype grouping, the
rates of weakly positive SHBG in group 1 (serous tumor), group 2
(mucinous and endometrioid tumors) and group 3 (clear cell,
mixed and undifferentiated tumors) were 25.2% (41/163), 45.9%
(17/37) and 14.8% (4/27) respectively, and strong SHBG
detection rates in these three groups were 41.1% (67/163),
18.9% (7/37) and 40.7% (11/27), respectively. As for FIGO stage,
weakly positive SHBG expression rates in stage I/II, III and IV
tumors were decreased from 34.8% (16/46), to 27.4% (32/117)
and then to 21.5% (17/79), and strongly positive SHBG
expression rates in these three groups were correspondingly
increased from 23.9% (11/46) to 36.8% (43/117) and then to
45.6% (36/79), respectively. In consideration of histological grade,
strong SHBG positivity from well, moderate to poor differentiated
tumors was significantly increased, from 15.8% (3/19) to 29.0%
(18/62) and then to 44.4% (59/133). Similarly, the percentage for
tumors of weakly positive SHBG from well, moderate to poor
differentiated tumors was correspondingly decreased. Linear-by-
linear Chi-square test showed a significantly positive association
between higher level of SHBG expression and poor histological
grade (p=0.020).
Survival Analyses
Statistically there were no significant associations between
SHBG expression and OS (p=0.220) or PFS (p=0.132), although
there was a negative association trend (Fig. 3). The median OS for
the 229 valid cases was 1.602 years with 95% confidence interval
(CI) at 1.188 to 2.015 years. The median PFS for the 232 valid
cases was 0.646 year with 95% CI at 0.501 to 0.791 year. The
Figure 1. SHBG expression in ovarian cancer cell lines. A. ICC. (a): weak SHBG immunodetection in ES-2 cell line; (b): moderate SHBG
immunodetection in SKOV-3 cell line; (c) and (d): strong SHBG immunodetection in OVCAR-3 cell line and OV-90 cell line, respectively; (e): negative
human liver tissue control with the same concentration of non-immune goat IgG; (f): positive human liver tissue control showing positive cytoplasmic
SHBG expression. All the photos were taken at 2006. B. Western blotting. It shows similar expression levels of SHBG as with ICC result in the four
ovarian cancer cell lines, i.e.: high expression in OV-90 and OVCAR-3 cell lines, moderate expression in SKOV-3 cell line and weak expression in ES-2
cell line.
doi:10.1371/journal.pone.0083238.g001
SHBG Expression in Ovarian Carcinomas
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median PFSs in the SHBG weakly positive group, moderately
positive group and strongly positive group were 0.802, 0.646, and
0.608 year respectively.
Discussion
Both female and male sex hormones play important roles in
ovarian carcinoma proliferation, invasiveness and metastasis
[29,30,31]. SHBG, known as sex hormone carrier protein, is
synthesized mainly in the liver and secreted into blood, regulating
the free concentration of the steroids that bind to it in plasma
[32,33,34]. Plasma SHBG is reduced by tumor necrosis factor-a
(TNF-a) via downregulating hepatocyte nuclear factor 4-a (HNF4-
a), a key transcription factor that regulates SHBG expression in
the liver [35]. SHBG can also participate in multiple signaling
pathways for certain steroid hormones on selected cell membranes.
It binds with high affinity to a specific membrane receptor
(RSHBG), forming the SHBG-RSHBG complex [36,37], and an
appropriate steroid binds to this complex and increases intracel-
lular cAMP in prostate and breast cancers [38,39,40]. As a result,
plasma SHBG is assumed to play a role in ovarian carcinoma
clinical behaviors. However, a case-control study of 132 ovarian
carcinoma patients with primary ovarian carcinomas and 264
controls in parallel from New York (USA), Umea (Sweden) and
Milan (Italy) did not reveal a strong relation between increasing
circulating SHBG and ovarian carcinoma risk [41], also confirmed
by Rinaldi and coworkers [42].
In the other hand, increasing number of studies confirms that
SHBG production is not limited in liver cells, although the
function of the locally synthesized SHBG in non-liver cells is not
clear at present. Forges and coworkers [43] detected SHBG in
human ovarian follicles and corpora lutea and indicated a
significant role for SHBG in regulating follicular maturation as
well as in luteal function. Intracellular expression of SHBG was
detected in breast cancer cell line MCF-7 both in mRNA level by
real-time PCR and protein level by Western blotting, and it was
proved to be dose-dependent of estrogen in the cell culture
medium [44]. Hryb and colleagues [21] investigated both SHBG
mRNA and protein in prostate cancer cell lines (LNCaP, PC 3,
and DU 145) as well as in cultured prostate stromal and epithelial
cells derived from patients with benign prostatic hyperplasia by
biochemical and immunocytochemical techniques, and reported
locally synthesized SHBG in the human prostate with an
autocrine/paracrine effect. The locally expressed SHBG was later
reported to be involved in the regulation of the responsiveness of
prostate and breast cells via multiple signaling pathways,
suggesting its role in prostate and breast carcinomas [20], which
was supported by a report of Nakhla et al. [45] stating that
Figure 2. IHC SHBG staining in clinical ovarian carcinoma samples. Representative weak (A), moderate (B, moderately differentiated tumor)
and strong (C, poorly differentiated tumor) are shown. Stronger SHBG immunostaining is shown at the invasive front of a poor-differentiated ovarian
carcinoma (D). Negative control performed in human liver tissue with the same concentration of non-immune goat IgG shows no staining in the liver
cells (E). Positive control performed with liver tissue shows the positive cytoplasm SHBG staining. Endothelial cells are also positive for SHBG. All
photos were taken at 2006.
doi:10.1371/journal.pone.0083238.g002
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aberrant SHBG expression in hormonally responsive tissues might
contribute to carcinogenesis.
Our present report is, to our best knowledge, the first study to
systematically assess the localization and clinicopathological
relations of the locally expressed SHBG in human ovarian
carcinomas. We detected SHBG expression in all the four human
ovarian cancer cell lines both by ICC and Western blotting,
confirming the intracellular expression of SHBG in different
histological subtype-derived cell lines. The OV-90 line which was
derived from the ascites of a patient with histological grade 3/stage
IIIC malignant papillary serous adenocarcinoma, expressed the
highest level of SHBG. The ES-2 line, derived from an ovarian
CCC with fibroblast morphology, expressed the lowest level of
SHBG.
In our present study, we did find that SHBG was significantly
highly expressed in the group of clear cell, mixed and undiffer-
entiated tumors, compared to the serous and mucinous/endocrine
groups. CCC in early stage (FIGO stage I) did reveal a favorable
prognosis as stage I serous carcinoma (SC), however CCC in
advanced stage (FIGO stage II, III and IV) was linked to a poor
clinical result [46]. Moreover, it is commonly known that CCC is
highly resistant to most chemotherapy regimens [46,47]. However
ES-2 line exhibits low to moderate resistance to a number of
chemotherapeutic agents including doxorubicin, cisplatin, car-
mustine, etoposide and cyanomorpholinodoxorubicin (MRA-CN)
[48], indicating that ES-2 cells may have better clinical
consequences than other CCC derived cell lines. Our finding that
the ES-2 cell line was weakly positive for SHBG may imply a
potential clinical role of SHBG in ovarian carcinoma although
functional SHBG studies in consideration of this are warranted.
Statistical analyses of histological subtype, histological grade and
FIGO stage confirmed increased SHBG expression in more
unfavorable ovarian carcinomas. Moreover, SHBG is expressed
significantly higher at the invasive front, known for epithelial–
Table 1. Comparison of clinical and pathologic characteristics by tumor SHBG intensity.
SHBG IHC score
1 (weak) 2 (moderate) 3 (strong) p value
N Total N 65 93 90
Age (years old): 0.200
#49 57 19 19 19
(33.3%) (33.3%) (33.3%)




Serous 163 41 55 67
(25.2%) (33.7%) (41.1%)
Muci+Endo 37 17 13 7
(45.0%) (35.1%) (18.9%)
Clea+Mixe+Undi 27 4 12 11
(14.8%) (44.4%) (40.7%)
Others or unclassified 21
FIGO Stage: 0.018
I+II 46 16 19 11
(34.8%) (41.3%) (23.9%)
III 117 32 42 43
(27.4%) (35.9%) (36.8%)
IV 79 17 26 36
(21.5%) (32.9%) (45.6%)
Not staged or missing 6
Histological Grade: 0.020
Well 19 6 10 3
(31.6%) (52.6%) (15.8%)
Moderate 62 18 26 18
(29.0%) (41.9%) (29.0%)
Poor 133 31 43 59
(23.3%) (32.3%) (44.4%)
Not graded or missing 34
Muci, Mucinous tumor; Endo, Endometrioid; Clea, Clear cell; Mixe, Mixed epithelial tumor; Undi, Undifferenciated tumor.
doi:10.1371/journal.pone.0083238.t001
SHBG Expression in Ovarian Carcinomas
PLOS ONE | www.plosone.org 5 December 2013 | Volume 8 | Issue 12 | e83238
Figure 3. OS and PFS for the ovarian carcinoma patients in 3 SHBG IHC groups. For both OS (A) and PFS (B) curves, weakly (IHC score 1),
moderately (IHC score 2) and strongly (IHC score 3) SHBG expressing groups were marked by blue, green and brown lines respectively. No statistically
significant difference was obtained both for OS (p=0.220) and PFS (p= 0.132).
doi:10.1371/journal.pone.0083238.g003
SHBG Expression in Ovarian Carcinomas
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mesenchymal transition or transformation (EMT) processes [49].
Here tumor budding (TB) takes place, detachment and migration
of small clusters of tumor cells from the neoplastic epithelium, of
importance for the local invasion and distant metastases [50,51].
This demonstrated that the local produced SHBG in ovarian
cancer cells might probably influence the proliferative activity,
invasiveness and distant metastasis of human ovarian carcinoma
cells. Thus, our findings are consistent with the previous reports on
the potential role of intracellular SHBG in other hormone-
targeting carcinomas [20,45].
Intriguingly, in salmonids the classic SHBG (SHBGa) mRNA
was reported to be mainly expressed in liver and spleen, but not
detected in the ovary, while a novel SHBGb had a predominant
ovarian expression but could not be detected in liver [5]. At least
six transcript variants of SHBG gene have been found in humans,
and four of them can encode different protein isoforms (http://
www.ncbi.nlm.nih.gov/gene/6462#). Both genetic factors and
environment factors may contribute to the multiplicity of SHBG
[52]. These variants may play an important role in some common
human diseases [52], including polycystic ovary syndrome (PCOS)
[53] and some cancers [54,55]. The genetic variation in SHBG
was implicated to influence prostate cancer susceptibility [54]. It is
currently unknown about SHBG variants in normal and
malignant ovarian tissues. Additional characterization of SHBG
variants may help to further understand the molecular and
biological roles of SHBG in ovarian carcinoma.
In summary, we have found that SHBG is expressed in ovarian
cancer cells, verified both in cell lines and clinical samples, and its
expression is associated with unfavorable clinicopathological
features. The SHBG variants and their potential molecular and
biological functions in human ovarian carcinoma are currently
under investigation in our laboratory.
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